MicroRNA Market Size was valued at USD 1.7 Billion in 2023. The MicroRNA market industry is projected to grow from USD 1.9 Billion in 2024 to USD 5.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.30% during the forecast period (2024 - 2032). Growing adoption in cancer diagnostics and therapeutics is one of the key market drivers enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for MicroRNA is being driven by the growing adoption of microRNAs in cancer diagnostics and therapeutics. Dysregulated microRNA expression profiles have been implicated in various aspects of cancer biology, including tumor initiation, progression, metastasis, and therapeutic resistance. As a result, microRNAs have emerged as promising biomarkers for cancer diagnosis, prognosis, and treatment response prediction. MicroRNA-based diagnostic assays enable early cancer detection, while microRNA-targeted therapeutics offer innovative approaches to cancer treatment. These include strategies to inhibit oncogenic microRNAs and restore tumor-suppressive microRNAs, thereby modulating cancer-related pathways and enhancing therapeutic efficacy. With ongoing research efforts focused on elucidating the role of microRNAs in cancer biology and advancing microRNA-based technologies, the demand for microRNA-based cancer diagnostics and therapeutics continues to grow, driving market expansion and innovation in the field.
The growing demand for personalized medicine is a key driver of the MicroRNA Market. MicroRNAs serve as valuable biomarkers for personalized medicine due to their tissue-specific expression patterns and dysregulation in various diseases. They play crucial roles in regulating gene expression and cellular processes implicated in disease development and progression. As a result, microRNAs are used for disease diagnosis, prognosis, and treatment response prediction. In personalized medicine, microRNA-based diagnostics enable the identification of individual patient profiles, facilitating tailored treatment approaches. Additionally, microRNA-based therapeutics offer novel strategies for personalized treatment interventions, including targeting specific microRNAs involved in disease pathways. With increasing recognition of the importance of individualized patient care and advances in microRNA research and technology, the demand for microRNA-based solutions in personalized medicine continues to rise, driving market growth and innovation in the field.
Rising investments in research and development (R&D) are pivotal drivers of the MicroRNA Market. Increased funding from government agencies, academic institutions, and biotechnology companies fuels innovation and accelerates advancements in microRNA-based technologies. These investments support fundamental research aimed at elucidating the roles of microRNAs in health and disease, as well as the development of novel microRNA-based diagnostics and therapeutics. Collaborative research initiatives and strategic partnerships between academia and industry foster knowledge exchange and technological transfer, driving market expansion. Furthermore, R&D investments enable the validation and clinical translation of microRNA biomarkers for disease diagnosis, prognosis, and treatment response prediction. With ongoing efforts to enhance understanding of microRNA biology and develop innovative applications, rising investments in R&D play a crucial role in driving the adoption and growth of microRNA-based solutions in healthcare, ultimately benefiting patients and healthcare providers alike. Thus, driving the MicroRNA market revenue.
For instance, MiRXES, a biotechnology company headquartered in Singapore, recently introduced several innovative initiatives. These include the establishment of an Industry 4.0 (i4.0) manufacturing facility, the inauguration of two additional laboratories, and the initiation of a collaborative research project focusing on multi-cancer screening. These advancements reflect MiRXES' commitment to enhancing its research and manufacturing capacities to create miRNA-based diagnostic tests for disease detection.
Consumables Product & Services are experiencing the highest Compound Annual Growth Rate (CAGR) in the MicroRNA Market due to increasing demand for reagents, kits, and assay consumables essential for microRNA analysis. These consumables are integral to sample preparation, RNA extraction, cDNA synthesis, and miRNA quantification, driving their widespread usage in research and diagnostics. Moreover, advancements in consumable technologies, such as the development of highly specific and sensitive assays, contribute to their rising adoption. As microRNA research expands and becomes more accessible, the demand for consumables continues to grow, fueling their exceptional market growth.
Figure 1: MicroRNA Market, by Product & Services, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The MicroRNA Market segmentation, based on application, includes Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Others. In 2023, The Cancer category generated the most income due to the significant role of microRNAs in cancer biology and the urgent need for improved diagnostic and therapeutic solutions. Dysregulated microRNA expression profiles serve as biomarkers for cancer diagnosis, prognosis, and treatment response prediction. Moreover, microRNAs regulate key processes involved in cancer initiation, progression, and metastasis. With the growing incidence of cancer worldwide and increasing research focus on microRNA-based cancer diagnostics and therapeutics, the cancer application segment maintains its leading position in the MicroRNA Market.
The Infectious Diseases application segment is experiencing the highest Compound Annual Growth Rate (CAGR) in the MicroRNA Market due to several factors. MicroRNAs play crucial roles in host-pathogen interactions and immune response modulation, making them valuable biomarkers for infectious diseases. With the global burden of infectious diseases and emerging pathogens, there is a growing need for rapid and accurate diagnostic tools. MicroRNA-based assays offer promise for early detection, prognosis, and monitoring of infectious diseases, driving their exceptional market growth.
The MicroRNA Market segmentation, based on end-use, includes Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Others. In 2023, The Biotechnology & Pharmaceutical Companies category generated the most income due to extensive research and development investments aimed at harnessing microRNAs for therapeutic and diagnostic applications. These companies leverage microRNA technologies to develop innovative drugs, including miRNA-based therapeutics for cancer and other diseases. Additionally, they drive market growth through collaborations, acquisitions, and licensing agreements to access cutting-edge microRNA technologies. With a focus on personalized medicine and precision diagnostics, biotech and pharma firms maintain their leading position in the MicroRNA Market.
Academic & Government Research Institutes End-Use is experiencing the highest Compound Annual Growth Rate (CAGR) in the MicroRNA Market due to several factors. These institutions drive fundamental research into microRNA biology, uncovering new insights into their roles in health and disease. Additionally, they play a crucial role in validating and translating microRNA discoveries into clinical applications, including diagnostics and therapeutics. With increasing funding support and collaborative efforts, academic and government research institutes are at the forefront of driving innovation and expanding the MicroRNA Market.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American MicroRNA market area will dominate this market, with significant investments in the biotechnology and pharmaceutical industries. North America leads the MicroRNA Market due to factors such as robust research infrastructure, significant investments in biotechnology and pharmaceutical industries, and a high prevalence of chronic diseases. Moreover, favorable regulatory policies and supportive reimbursement frameworks encourage the adoption of microRNA-based diagnostics and therapeutics in the region. Additionally, strong collaborations between academia, industry, and government facilitate innovation and drive market growth. With a focus on precision medicine and personalized healthcare, North America maintains its dominance in the MicroRNA Market.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: MICRORNA MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe MicroRNA market accounts for the second-largest market share due to the substantial investments in life sciences research. Europe holds the second-largest share in the MicroRNA Market due to a well-established healthcare infrastructure, substantial investments in life sciences research, and a growing emphasis on personalized medicine. The region benefits from strong collaborations between academic institutions, biotech companies, and healthcare providers, fostering innovation in microRNA-based diagnostics and therapeutics. Additionally, supportive regulatory frameworks and reimbursement policies encourage the adoption of advanced molecular diagnostics. With a focus on addressing unmet medical needs and improving patient outcomes, Europe maintains its significant presence in the MicroRNA Market. Further, the German MicroRNA market held the largest market share, and the UK MicroRNA market was the fastest growing market in the European region.
The Asia-Pacific MicroRNA Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region experiences the highest Compound Annual Growth Rate (CAGR) in the MicroRNA Market due to several factors. These include increasing investments in healthcare infrastructure, rising research and development activities, and a growing prevalence of chronic diseases. Additionally, expanding collaborations between academia, industry, and government drive innovation and adoption of microRNA-based technologies. With a large and aging population, coupled with rising healthcare expenditures and demand for advanced diagnostics and therapeutics, Asia Pacific presents significant growth opportunities in the MicroRNA Market. Moreover, China’s MicroRNA market held the largest market share, and the Indian MicroRNA market was the fastest growing market in the Asia-Pacific region.
Leading players such as Qiagen, Thermo Fisher Scientific, Merck KGaA, NanoString Technologies, and Exiqon are expanding their product portfolios to offer comprehensive solutions for microRNA analysis. These companies focus on developing advanced instruments, reagents, and software platforms for microRNA profiling, quantification, and functional analysis. Additionally, strategic collaborations, acquisitions, and partnerships strengthen their market developments and drive innovation in MicroRNA industry diagnostics and therapeutics.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global MicroRNA industry to benefit clients and increase the market sector. In recent years, the MicroRNA industry has offered some of the most significant advantages to instruments. Major players in the MicroRNA market, including Qiagen, Thermo Fisher Scientific, Merck KGaA, NanoString Technologies, Exiqon, Illumina, Inc., Agilent Technologies, Bio-Rad Laboratories, Inc., New England Biolabs, Roche Diagnostics and others, are attempting to increase market demand by investing in research and development operations.
Qiagen is a leading player in the MicroRNA Market, offering a comprehensive range of products and services for microRNA analysis and research. The company provides innovative solutions for microRNA isolation, quantification, profiling, and functional analysis, catering to the needs of academic researchers, pharmaceutical companies, and diagnostic laboratories worldwide. Qiagen's portfolio includes advanced instruments, such as the QIAcube and QIAseq platforms, as well as high-quality reagents, kits, and bioinformatics software for microRNA research. With a focus on precision diagnostics and personalized medicine, Qiagen continues to drive innovation in microRNA-based technologies, enabling breakthroughs in disease diagnosis, prognosis, and treatment. Additionally, the company's strong global presence and strategic collaborations reinforce its position as a trusted partner in the MicroRNA Market.
NanoString Technologies is a prominent player in the MicroRNA Market, specializing in the development and commercialization of innovative molecular diagnostic and research tools. The company's flagship product, the nCounter Analysis System, offers a high-throughput, multiplexed solution for quantifying and profiling microRNAs with exceptional sensitivity and specificity. NanoString's technology enables researchers and clinicians to analyze microRNA expression patterns in diverse sample types, facilitating biomarker discovery and validation for disease diagnosis, prognosis, and treatment response prediction. With a focus on precision medicine and personalized diagnostics, NanoString continues to drive innovation in microRNA analysis, empowering researchers and healthcare professionals to unlock new insights into disease biology and advance patient care.
Key Companies in the MicroRNA market include
February 2022: At the University of Illinois Urbana, researchers have created a novel microRNA point-of-care test for detecting cancer. This test employs nanoparticles to capture microRNAs (miRNAs) specific to tumors present in human serum.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.7 Billion |
| Market Size 2024 | USD 1.9 Billion |
| Market Size 2032 | USD 5.2 Billion |
| Compound Annual Growth Rate (CAGR) | 13.30% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Products & Services, Application, End-Use, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Qiagen, Thermo Fisher Scientific, Merck KGaA, NanoString Technologies, Exiqon, Illumina, Inc., Agilent Technologies, Bio-Rad Laboratories, Inc., New England Biolabs and Roche Diagnostics |
| Key Market Opportunities | · Cardiovascular Disease Management, Cancer Diagnostics and Therapeutics and Biopharmaceutical Research and Development |
| Key Market Dynamics | · Growing Adoption in Cancer Diagnostics and Therapeutics and Growing Demand for Personalized Medicine |
Frequently Asked Questions (FAQ) :
The MicroRNA Market size was valued at USD 1.9 Billion in 2023.
The global market is projected to grow at a CAGR of 13.30% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Qiagen, Thermo Fisher Scientific, Merck KGaA, NanoString Technologies, Exiqon, Illumina, Inc., Agilent Technologies, Bio-Rad Laboratories, Inc., New England Biolabs and Roche Diagnostics Company.
The instruments category dominated the market in 2023.
The cancer category had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
